Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:CPRI
NYSE:CPRILuxury

Is Capri Holdings (CPRI) Still Attractive After Recent Share Price Volatility?

Investors may be wondering whether Capri Holdings shares still offer value after a turbulent few years, or if most of the opportunity is already reflected in the current price. The stock last closed at US$19.88, with returns of 10.7% over 7 days, 7.0% over 30 days, an 18.5% decline year to date and a 35.7% gain over the past year, while 3 and 5 year returns stand at 55.3% and 63.1% declines respectively. Recent price moves have come as investors reassess the brand portfolio and the broader...
TSX:EQX
TSX:EQXMetals and Mining

Equinox Gold Shifts To Cash Returns With Strong Q1 And Lower Debt

Equinox Gold reported strong Q1 2026 operational results, highlighting solid performance across its mines. The company accelerated expansion of its Canadian operations, reinforcing the importance of these assets after exiting Brazil. Following the divestment of its Brazilian portfolio, Equinox Gold repaid CA$990 million in debt and strengthened its balance sheet. The company introduced its inaugural dividend, signaling a new phase of direct shareholder returns. For investors tracking...
NasdaqGS:NEOG
NasdaqGS:NEOGMedical Equipment

Neogen Reshapes Portfolio Around Food Safety With Divestitures And Job Cuts

Neogen has agreed to sell its Genomics business to Zoetis as part of a wider portfolio reshaping. The company has completed the divestiture of its Cleaners and Disinfectants business. Neogen is implementing a major restructuring, including a 10% global headcount reduction. These actions concentrate the business around its core Food Safety segment and streamline operations. For investors watching NasdaqGS:NEOG, these moves come after a mixed share price history. The stock is at $9.42, with a...
NasdaqGS:JAZZ
NasdaqGS:JAZZPharmaceuticals

Is It Too Late To Consider Jazz Pharmaceuticals (JAZZ) After A 93% One Year Rally?

If you are wondering whether Jazz Pharmaceuticals at around US$194.20 is still offering value after a strong run, the key is to look closely at what the current price actually reflects. The stock has posted returns of 3.9% over the last 7 days, 8.8% over 30 days, 12.2% year to date, and 93.2% over the past year, which naturally raises questions about how much of the story is already priced in and how risk is being perceived. Recent attention on Jazz Pharmaceuticals has centered on its...
NasdaqGM:FUTU
NasdaqGM:FUTUCapital Markets

Is It Time To Reassess Futu Holdings (FUTU) After Its Strong Multi‑Year Price Run?

If you are wondering whether Futu Holdings at US$154.50 is still reasonably priced after a strong run, the next sections will focus squarely on what the current share price might imply about value. The stock has returned 10.2% over the past week and 9.5% over the past month, with a 92.2% return over the last year but a 13.4% decline year to date and a 230.6% return over three years and 3.3% over five years. Recent coverage has highlighted Futu Holdings as a prominent online brokerage play...
XTRA:EOAN
XTRA:EOANIntegrated Utilities

Is It Too Late To Consider E.ON (XTRA:EOAN) After Strong Multi Year Gains?

Wondering whether E.ON at €19.59 still offers value or if most of the opportunity is already priced in? This article walks through what the current share price might be telling you. The stock has eased slightly in the short term, with a 0.6% decline over 7 days and a 1.6% decline over 30 days, while longer term returns sit at 19.1% year to date, 40.4% over 1 year, 88.0% over 3 years and 147.4% over 5 years. Recent coverage has focused on E.ON as a core European utilities name, highlighting...
NasdaqGS:MEDP
NasdaqGS:MEDPLife Sciences

Medpace Lawsuits And CEO Sales Test Growth Story And Valuation

Medpace Holdings (NasdaqGS:MEDP) is facing multiple shareholder class action lawsuits tied to alleged false and misleading statements about its book to bill ratio and backlog cancellation rates. Investors claim they suffered losses after company disclosures, with recent insider stock sales by the CEO shortly before negative updates adding to concerns. The litigation focuses on whether management provided overly optimistic projections that did not align with internal business conditions. For...
SEHK:823
SEHK:823Retail REITs

A Look At Link REIT (SEHK:823) Valuation After Singapore Asset Sale And Buyback Plans

Link Real Estate Investment Trust (SEHK:823) has agreed to sell its 56% stake in Singapore retail property Swing By@Thomson Plaza for SGD250 million, at a premium to both its book value and its acquisition price. See our latest analysis for Link Real Estate Investment Trust. The Swing By@Thomson Plaza sale comes after a period of stronger price momentum, with a 7 day share price return of 5.18% and a 90 day share price return of 11.44%. The 1 year total shareholder return of 24.00% contrasts...
NasdaqGS:FRSH
NasdaqGS:FRSHSoftware

Freshworks Taps Kuntal Vahalia To Drive Partner Channel Upmarket Push

Freshworks (NasdaqGS:FRSH) appointed Kuntal Vahalia as Senior Vice President, Partnership Channel. Vahalia will lead the company’s global partner strategy with a focus on the partner channel. The role includes supporting Freshworks’ efforts to move further upmarket and deepen ties with global system integrators. For investors tracking SaaS platforms, Freshworks operates in the customer and employee experience software space, where partner ecosystems often influence how quickly products...
NasdaqGS:FIVE
NasdaqGS:FIVESpecialty Retail

Five Below Results And New Store Opening Test High P/E Expectations

Five Below (NasdaqGS:FIVE) reported strong quarterly results, with revenue and earnings exceeding analyst expectations. The company opened a new store in Corbin, Kentucky, adding to its growing brick and mortar footprint. Management, led by CEO Winnie Park, highlighted ongoing progress on key business initiatives alongside the latest store launch. Five Below enters this update cycle with its shares at $217.37 and a very large 1 year return of 259.5%. The company has also recorded a 12.4%...
NasdaqGM:WINA
NasdaqGM:WINASpecialty Retail

Is It Too Late To Consider Winmark (WINA) After Its Strong Share Price Run?

If you are wondering whether Winmark at around US$444 per share offers good value or if you might be arriving late, this piece lays out the key facts so you can judge the price for yourself. The stock has recently moved 3.2% over the last 7 days, with a 1 year return of 37.5% and 10.6% year to date. The 30 day return sits at a 1.2% decline and the 3 and 5 year returns are 46.1% and 163.2% respectively. Recent attention around Winmark has focused on its position in the Specialty Retail space...
NYSE:VTR
NYSE:VTRHealth Care REITs

Is It Time To Reassess Ventas (VTR) After Its Strong 1-Year Share Price Run?

If you are wondering whether Ventas at around US$84.96 is offering fair value or a stretched price, you are in the right place for a clear valuation breakdown. The stock has returned 2.0% over the last week, 9.9% year to date and 32.0% over the past year. Over the last 30 days it has declined 1.8%, which may have shifted some investors' sense of risk and opportunity. Recent coverage has focused on Ventas in the context of its role as a health care focused REIT, with attention on how its...
NasdaqGM:NNNN
NasdaqGM:NNNNBiotechs

Anbio Biotechnology Broadens Test Portfolio And Shifts Risk Profile

Anbio Biotechnology, NasdaqGM:NNNN, is expanding beyond COVID-19 diagnostics into a broader test portfolio. The company is rolling out new rapid immunoassay and PCR platforms across human health, veterinary, and multi-disease applications. This move reflects a business model shift toward more diversified diagnostic revenues and reduced reliance on legacy COVID-19 products. For you as an investor, this repositioning matters because Anbio Biotechnology is moving from a single product focus...
XTRA:SPG
XTRA:SPGMedia

Does Springer Nature KGaA (XTRA:SPG) Offer Value After Recent Double‑Digit Monthly Gain?

If you are wondering whether Springer Nature KGaA at €17.32 is priced fairly or offering hidden value, this article breaks down what the current numbers are really saying about the stock. Over the last week, the share price return sits at 1.6%, with a 30 day return of 13.1%. The year to date return of 12.5% and 1 year return of 7.4% give you a wider context for how the stock has been treating investors recently. Recent coverage has focused on providing investors with an evergreen view of...
ASX:STK
ASX:STKMetals and Mining

Strickland Metals (ASX:STK) Is Up 12.2% After Funding 70,000m Rogozna Drill Push – Has The Bull Case Changed?

Strickland Metals has advanced its 8.6Moz AuEq Rogozna Project in Serbia, confirming carbonate replacement lead-zinc-silver mineralisation at Obradov Potok and funding an extensive 2026 drilling programme with a recent A$55,000,000 placement. This combination of a large-scale gold resource, validation of a copper-gold skarn exploration model, and backing from major shareholder Zijin Mining reframes Rogozna as a potential cornerstone European gold development. We’ll now examine how the...
NYSE:EQT
NYSE:EQTOil and Gas

EQT Deepens LNG Ties With Commonwealth And Glencore To Shape Future Cash Flows

EQT (NYSE:EQT) agreed to purchase an additional 1 million metric tons of LNG per year from Commonwealth LNG, bringing its total contracted volume to 2 million tons annually. Glencore now has long-term commitments for 3 million tons of LNG per year from Commonwealth LNG. With these contracts, Commonwealth LNG reports that 8 of its planned 9.5 million tons of annual capacity is now under long-term agreements. EQT is a major U.S. natural gas producer, and this latest LNG deal increases its...
NYSE:PRGO
NYSE:PRGOPharmaceuticals

Is Perrigo (PRGO) Pricing Reflect Its Recent Rebound And Weak Long Term Returns

Wondering whether Perrigo's current share price makes sense or if the market has mispriced it? This article walks through the key valuation clues that can help you frame that question. The stock has seen a 0.1% move over the last 7 days and a 16.8% return over the past month, set against a much tougher picture with a 21.8% decline year to date and a 52.9% fall over the last year, as well as 65.7% and 68.3% declines over 3 and 5 years respectively. Recent attention on Perrigo has focused less...
NasdaqCM:ASPI
NasdaqCM:ASPIChemicals

ASP Isotopes (ASPI) Revenue Surge Tests Bullish Growth Narratives Against Deepening Losses

ASP Isotopes (ASPI) has just put out its FY 2025 numbers, with Q4 revenue of about US$16.7 million and a Q4 basic EPS loss of US$0.76. Trailing twelve month revenue sits at roughly US$23.8 million against a TTM basic EPS loss of US$2.11. The company has seen quarterly revenue move from around US$1.2 million in Q4 FY 2024 to US$16.7 million in Q4 FY 2025, while trailing twelve month revenue shifted from about US$4.1 million to US$23.8 million over the same window. Investors will now be...